These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 39159706)

  • 1. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.
    Reduzzi C; Nicolo' E; Singhal S; Venetis K; Ortega-Franco A; de Miguel-Perez D; Dipasquale A; Gouda MA; Saldanha EF; Kasi PM; Jantus-Lewintre E; Fusco N; Malapelle U; Gandara DR; Rolfo C; Serrano MJ; Cristofanilli M;
    Crit Rev Oncol Hematol; 2024 Nov; 203():104483. PubMed ID: 39159706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid Biopsy in the Clinical Management of Cancers.
    Ho HY; Chung KK; Kan CM; Wong SC
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
    Seyhan AA
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking cancer progression: from circulating tumor cells to metastasis.
    Castro-Giner F; Aceto N
    Genome Med; 2020 Mar; 12(1):31. PubMed ID: 32192534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
    Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
    Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.
    Mentis AA; Grivas PD; Dardiotis E; Romas NA; Papavassiliou AG
    Cell Mol Life Sci; 2020 Sep; 77(18):3671-3690. PubMed ID: 32333084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.
    Liebs S; Eder T; Klauschen F; Schütte M; Yaspo ML; Keilholz U; Tinhofer I; Kidess-Sigal E; Braunholz D
    Oncogene; 2021 Aug; 40(33):5204-5212. PubMed ID: 34230613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
    Giannopoulou L; Kasimir-Bauer S; Lianidou ES
    Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy: novel technologies and clinical applications.
    Reimers N; Pantel K
    Clin Chem Lab Med; 2019 Feb; 57(3):312-316. PubMed ID: 30465714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of circulating biomarkers in liquid biopsy diagnostics.
    Yeo JC; Lim CT
    Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook.
    Tinhofer I; Staudte S
    Expert Rev Mol Diagn; 2018 Oct; 18(10):897-906. PubMed ID: 30199647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy in prostate cancer: A novel dual biomarker analysis approach integrating circulating tumor cells and circulating tumor DNA data.
    Li Q; Tang L; Zhao Y; Li Z; Ma W; Ma L
    Cell Mol Biol (Noisy-le-grand); 2024 Sep; 70(8):158-163. PubMed ID: 39262247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of liquid biopsy in precision medicine: opportunities and challenges.
    Wang J; Chang S; Li G; Sun Y
    Front Med; 2017 Dec; 11(4):522-527. PubMed ID: 28744793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
    Morrison GJ; Goldkorn A
    Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as promising novel biomarkers in solid cancers.
    Lianidou ES; Strati A; Markou A
    Crit Rev Clin Lab Sci; 2014 Jun; 51(3):160-71. PubMed ID: 24641350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells in breast cancer: applications in personalized medicine.
    Lee JS; Magbanua MJM; Park JW
    Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.